More than half of the patients who were taking the common generic drugs — valsartan, irbesartan and losartan — were in the U.S.
Not all generic products were affected, nor are the brand-name versions of the blood-pressure medication.
The FDA learned last summer that some generic versions of the blood pressure drugs, called angiotensin II receptor blockers, contained nitrosamine impurities. The impurities, N-Nitrosodimethylamine and N-Nitrosodiethylamine, are likely carcinogenic.
The discovery initially prompted recalls of just a few drugs containing the impurity, but the list of recalls has grown. The most recent recall was announced last week.
The FDA has been investigating the root cause of the issue.
More articles on pharmacy:
Cancer therapy prices prevent access to treatment, WHO says
Despite controversies, J&J ranks among Fortune’s most-admired companies
Bristol-Myers swings to $1.2B profit in Q4
